As a core frontier in modern biopharmaceuticals, antibodies and Antibody-Drug Conjugates (ADCs) have emerged as critical breakthroughs in the treatment of major diseases—such as cancer and autoimmune disorders—thanks to their highly specific targeting capabilities and potent cytotoxic effects. Begelang provides comprehensive process equipment solutions spanning the entire workflow: from cell culture, antibody expression, and protein purification to ADC conjugation and purification. Through high-precision, high-stability systems, we ensure the activity, purity, and conjugation efficiency of antibody-based therapeutics. Our technologies cover the complete lifecycle of development and manufacturing for monoclonal antibodies, bispecific antibodies, and ADCs, empowering our clients to achieve their industrial objectives of delivering precision medicine, minimizing toxic side effects, and enhancing therapeutic efficacy.

Vaccines serve as the cornerstone for the prevention and control of infectious diseases, as well as for establishing herd immunity barriers. Spanning the spectrum from traditional inactivated and attenuated vaccines to next-generation technologies—such as recombinant protein, viral vector, and mRNA vaccines—Begrand provides integrated process systems designed for efficient cell expansion, virus culture, antigen purification, concentration, and sterile processing to support both vaccine R&D and large-scale manufacturing. Our equipment strictly adheres to GMP standards, balancing high yield, exceptional stability, and uncompromising safety to facilitate the rapid industrialization of both prophylactic and innovative therapeutic vaccines, thereby empowering our clients to achieve breakthroughs in critical fields such as influenza, HPV, COVID-19, and oncology vaccines.

As the "Third Medical Revolution," Cell and Gene Therapy (CGT) tackles cancer, rare diseases, and genetic disorders at their root by repairing, modifying, or replacing abnormal genes and cells. Begrand maintains a deep focus on the CGT sector, providing a comprehensive suite of process equipment and cleanroom solutions spanning the entire value chain—including cell isolation, activation, gene editing, expansion and culture, viral vector production, and formulation and filling. Our systems are compatible with a wide range of cutting-edge technologies—such as CAR-T, CAR-NK, stem cells, and AAV—and feature automated, closed, and modular designs. By ensuring the high activity, purity, and safety of these "living drugs," we empower our clients to achieve the medical breakthrough of "one treatment, lasting cure."

Plasmid DNA and linear DNA serve as core raw materials and critical vectors for gene therapy, DNA vaccines, mRNA vaccines, and CAR-T cell therapies. As the "molecular transport vehicles" of biotechnology, high-quality plasmids directly determine the safety and efficacy of downstream therapeutics. Begelang specializes in core processes—including plasmid construction, high-density fermentation, efficient cell lysis, precision purification, and concentration-sterilization—providing comprehensive equipment and engineering services spanning the entire workflow, from laboratory R&D to large-scale industrial production. Our systems ensure a high recovery rate of supercoiled plasmids, low endotoxin levels, and the absence of host-cell residues, thereby meeting the stringent requirements for GMP-grade plasmid DNA within the CGT, vaccine, and recombinant protein drug sectors.